Daewoong Pharmaceuticals announced that Nabota (botulinum toxin type A) has achieved cumulative sales exceeding 1 trillion won (approximately $750 million USD), a milestone underscoring the Korean toxin maker's penetration in Asian markets and growing export presence.
Nabota competes primarily in Asia-Pacific and select European markets, where it has built strong relationships with practitioners and medical spas. The milestone reflects both volume growth and pricing power in regions where Allergan's Botox faces less regulatory entrenchment and where practitioners seek alternatives with competitive rebate structures.